Embecta (EMBC) Competitors $15.18 +0.10 (+0.66%) As of 01:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EMBC vs. LIVN, WRBY, INSP, LQDA, PRCT, LMAT, AORT, EYE, ENOV, and CNMDShould you be buying Embecta stock or one of its competitors? The main competitors of Embecta include LivaNova (LIVN), Warby Parker (WRBY), Inspire Medical Systems (INSP), Liquidia Technologies (LQDA), PROCEPT BioRobotics (PRCT), LeMaitre Vascular (LMAT), Artivion (AORT), National Vision (EYE), Enovis (ENOV), and CONMED (CNMD). These companies are all part of the "medical equipment" industry. Embecta vs. Its Competitors LivaNova Warby Parker Inspire Medical Systems Liquidia Technologies PROCEPT BioRobotics LeMaitre Vascular Artivion National Vision Enovis CONMED LivaNova (NASDAQ:LIVN) and Embecta (NASDAQ:EMBC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings. Do institutionals and insiders hold more shares of LIVN or EMBC? 97.6% of LivaNova shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 0.3% of LivaNova shares are owned by insiders. Comparatively, 0.4% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to LIVN or EMBC? In the previous week, LivaNova had 6 more articles in the media than Embecta. MarketBeat recorded 11 mentions for LivaNova and 5 mentions for Embecta. LivaNova's average media sentiment score of 1.36 beat Embecta's score of 1.18 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, LIVN or EMBC? LivaNova has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Embecta has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Is LIVN or EMBC more profitable? Embecta has a net margin of 7.58% compared to LivaNova's net margin of -16.13%. LivaNova's return on equity of 14.57% beat Embecta's return on equity.Company Net Margins Return on Equity Return on Assets LivaNova-16.13% 14.57% 6.91% Embecta 7.58%-23.40%14.46% Do analysts recommend LIVN or EMBC? LivaNova presently has a consensus price target of $59.71, suggesting a potential upside of 8.76%. Embecta has a consensus price target of $19.00, suggesting a potential upside of 25.16%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than LivaNova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LivaNova 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Embecta 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has stronger earnings & valuation, LIVN or EMBC? Embecta has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLivaNova$1.31B2.29$63.23M-$3.89-14.11Embecta$1.12B0.79$78.30M$1.4310.62 SummaryLivaNova and Embecta tied by winning 8 of the 16 factors compared between the two stocks. Get Embecta News Delivered to You Automatically Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EMBC vs. The Competition Export to ExcelMetricEmbectaMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$889.05M$7.51B$5.72B$10.27BDividend Yield4.00%2.80%5.72%4.60%P/E Ratio10.6374.7875.7726.39Price / Sales0.7936.14493.51166.99Price / Cash4.5024.0725.8129.90Price / Book-1.197.9612.856.30Net Income$78.30M$241.92M$3.29B$270.30M7 Day Performance-0.33%-0.01%0.37%1.98%1 Month Performance10.88%2.69%4.74%6.16%1 Year Performance-7.83%2.90%68.88%27.93% Embecta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EMBCEmbecta4.518 of 5 stars$15.18+0.7%$19.00+25.2%-5.9%$889.05M$1.12B10.632,100News CoveragePositive NewsLIVNLivaNova3.099 of 5 stars$58.32+0.6%$59.71+2.4%+14.2%$3.17B$1.25B-14.992,900Positive NewsWRBYWarby Parker1.5089 of 5 stars$26.74+2.8%$24.06-10.0%+80.0%$2.74B$771.32M-382.003,780Positive NewsAnalyst UpgradeInsider TradeINSPInspire Medical Systems4.9032 of 5 stars$83.51-3.4%$164.50+97.0%-60.3%$2.56B$802.80M48.271,246Positive NewsLQDALiquidia Technologies3.6574 of 5 stars$27.98-3.0%$32.11+14.8%+173.3%$2.48B$14M-16.4650Positive NewsPRCTPROCEPT BioRobotics3.1603 of 5 stars$38.92-4.3%$73.22+88.1%-53.2%$2.26B$224.50M-25.11430Positive NewsAnalyst ForecastLMATLeMaitre Vascular3.1853 of 5 stars$97.07-0.4%$97.60+0.5%+3.0%$2.21B$219.86M47.12490Positive NewsAORTArtivion2.8938 of 5 stars$43.34-0.3%$40.63-6.2%+57.4%$2.05B$388.54M-103.191,600Positive NewsEYENational Vision2.4081 of 5 stars$23.08-1.7%$24.73+7.1%+117.0%$1.86B$1.82B-128.2213,411Positive NewsENOVEnovis4.04 of 5 stars$31.39-2.3%$51.00+62.5%-25.4%$1.84B$2.11B-2.207,367Positive NewsCNMDCONMED4.2404 of 5 stars$53.78-2.2%$59.80+11.2%-31.3%$1.70B$1.31B15.233,900Insider Trade Related Companies and Tools Related Companies LIVN Alternatives WRBY Alternatives INSP Alternatives LQDA Alternatives PRCT Alternatives LMAT Alternatives AORT Alternatives EYE Alternatives ENOV Alternatives CNMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EMBC) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EMBC Stock Alerts